Company news

Qiagen N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

QIAGEN reports preliminary Q3 2026 results

October 21, 2026

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

October 21, 2026

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

October 13, 2026

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

October 6, 2026

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

September 28, 2026

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

September 24, 2026

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

September 18, 2026

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

August 27, 2026

QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

August 24, 2026

2026 Annual Report 2026 IFRS Half Year Report

August 20, 2026

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

August 10, 2026

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

August 5, 2026

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

July 15, 2026

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

July 15, 2026

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

July 14, 2026

Qiagen N announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031

July 7, 2026

Qiagen N announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 2032

July 7, 2026

Qiagen N announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2027

July 7, 2026

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

June 15, 2026

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

May 28, 2026

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

May 20, 2026

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

May 19, 2026

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

May 12, 2026

QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

May 7, 2026

QIAGEN Reports Full Results for Q1 2026

May 6, 2026

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

April 27, 2026

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

April 16, 2026

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

April 14, 2026

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

March 31, 2026

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

March 20, 2026

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

March 19, 2026

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

March 10, 2026

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

February 19, 2026

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

February 4, 2026

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

February 3, 2026

QIAGEN Appoints Mark Stevenson to Supervisory Board

January 26, 2026

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

January 19, 2026

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

January 12, 2026

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

December 18, 2025

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

November 10, 2025

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

November 4, 2025

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

November 4, 2025

QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

October 30, 2025

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

October 28, 2025

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

October 13, 2025

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

September 10, 2025

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

September 2, 2025

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

August 28, 2025

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

August 28, 2025

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

August 28, 2025

Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 131 decks. Every deck is listed under its year.